Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: Communication from the SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 5, 2014, Pages 801-804

  Harenberg, J ^a   Du, S ^a   Weiss, C ^a   Kramer R ^a   Hoppensteadt, D ^b   Walenga, J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THROMBOPLASTIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; IN VITRO STUDY; MEDICAL SOCIETY; PRIORITY JOURNAL; BLOOD; BLOOD CLOTTING; CHEMISTRY; DIAGNOSTIC PROCEDURE; DRUG EFFECTS; DRUG MONITORING; HEMOSTASIS; HUMAN; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; REPRODUCIBILITY; STANDARDS; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CLINICAL LABORATORY TECHNIQUES; DRUG MONITORING; GUIDELINES AS TOPIC; HEMOSTASIS; HUMANS; INTERNATIONAL COOPERATION; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; THROMBOPLASTIN; THROMBOSIS;

EID: 84901191606     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12547     Document Type: Article

References (19)

1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
2. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012; 94: 257-64.
3. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
4. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
5. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now!. Thromb J 2013; 11: 8. doi: 10.1186/1477-9560-11-8.
6. Harenberg J, Marx S, Erdle S, Krämer R. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012; 5: 107-13.
7. Samama MM, Amiral J, Guinet C, Le Flem L, Seghatchian J. Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev Hematol 2013; 6: 155-64.
8. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11(Suppl 1): 122-8.
9. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-94.
10. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014; 111: 240-8.
11. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-71.
12. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-72.
13. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, LaCreta F. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-87.
14. Harenberg J, Marx S, Weiss C, Krämer R, Samama M, Schulman S. Subcommittee on control of anticoagulation of the ISTH. Report of the subcommittee of control of anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10: 1433-6.
15. Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 2013; 69: 1617-33.
16. Maloney CJ. Significance tests for Grubb's estimators. Biometrics 1970; 26: 671-5.
17. Spyropoulos AC, Douketis JD, Gerotziafas G, Kaatz S, Ortel TL, Schulman S. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost 2012; 10: 692-4.
18. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working Group on Perioperative Haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013; 106: 382-93.
19. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL, Rivaroxaban Prothrombin Time Field Trial Laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18: 150-8.